Priovant Therapeutics announced the enrollment of the first patients in its Phase 3 BEACON+ study evaluating brepocitinib for cutaneous sarcoidosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE